<DOC>
	<DOC>NCT01395927</DOC>
	<brief_summary>The purpose of this study is to evaluate blood levels of canagliflozin in healthy volunteers before and after the administration of multiple-doses of rifampin.</brief_summary>
	<brief_title>A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers</brief_title>
	<detailed_description>This is an open-label (volunteer and study staff will know the identity of study drugs assigned) study of canagliflozin and rifampin taken in a sequential order by healthy volunteers for up to 12 days. Healthy volunteers will take orally (by mouth) one 300 mg canagliflozin tablet and/or two 300 mg rifampin capsules daily in sequential order as follows: on Day 1 volunteers will take one 300-mg canagliflozin tablet, on Days 4 to 9 volunteers will take two 300-mg rifampin capsules once daily, on Day 10 volunteers will take one 300-mg canagliflozin tablet + two 300-mg rifampin capsules, and on Days 11 and 12 volunteers will take two 300-mg rifamplin capsules once daily.</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Healthy volunteers with a body mass index between 18 and 30 kg/m2 (inclusive) History of or current medical illness deemed clinically significant by the Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Canagliflozin</keyword>
	<keyword>Rifampin</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>